BIOAOREG Launches China's First Hyaluronic Acid-Enhanced Bone Graft Material: Aoxu® Bone Filler

Currently, oral health has increasingly become a focal point of public attention.Tooth loss, alveolar bone resorption, and other issuesseverely impairing patients' quality of life. With the intensifying aging of the population and heightened health awareness among residents, the global market for prosthodontics has been expanding year by year, and the demand for prosthodontic services is poised for explosive growth.Bone Grafting MaterialsAs an important auxiliary material, it plays a crucial role in it.

Bone Grafting MaterialsIt is primarily used to address insufficient bone volume following tooth loss, providing adequate bony support for dental implants. Traditional bone grafting materials are mostlyAutologous bone, allogeneic bone, or synthetic materials, but these materials each have their own advantages and disadvantages in clinical applications. Autologous bone grafts are limited by donor site availability and involve significant surgical trauma; allogeneic bone grafts carry a risk of immune rejection; while synthetic materials exhibit certain limitations in terms of biocompatibility and mechanical properties. In recent years, there has been a growing market demand for novel bone filler materials that are highly efficient, safe, and easy to handle. With the cross-disciplinary integration of biotechnology and materials science, the research and development of bone filler materials is gradually moving towardsMore Efficient, Safer, and More Biocompatibledirection.

Shaanxi BioRegen Regenerative Medicine Co., Ltd.(hereinafter referred to as “BioRegen”) has achieved three world-class scientific research accomplishments since its establishment. The company’s core team isEarliest in ChinaA team dedicated to regenerative medicine research. As the first recipient of the First-Class National Award for Progress in Science and Technology in the field of regenerative medicine, with its achievements twice recognized as one of the “Top Ten Advances in Chinese Pharmaceutical Biotechnology,” it is a pioneer in innovative R&D of regenerative medicine in China. To meet the demands in the field of oral bone regeneration, BioRegenIndependently developed “Aosu—China’s First Xenogeneic Bovine-Derived & Hyaluronic Acid Bone Filling Material,” filling the domestic gap in this field., providing more efficient solutions for clinical oral osseointegration.

On Tuesday, July 2, at 19:30, the 71st session of VCBeat Select New Product Review will feature Zhao Zheng, Director, Vice President, and Board Secretary of Shaanxi Bio-Restorative Medical Co., Ltd.; Zhang Yongjie, Chief Technology Officer of Shaanxi Bio-Restorative Medical Co., Ltd.; and Wang Peng, General Manager of the Regenerative Medicine Dental Division of Shaanxi Bio-Restorative Medical Co., Ltd., who will present"China's First Aosu® Hyaluronic Acid Bone Powder"product promotion.

Aosu Bone Graft MaterialSelection of calf cancellous bone, compositeHyaluronic AcidGelHyaluronic acid, a polysaccharide naturally present in the human body, exhibits excellent biocompatibility and promotes tissue regeneration, and is therefore widely used in the medical field.

Hyaluronic acid combined with bovine-derived bone particles has been developed into a bone graft material with excellent properties. This material retains the favorable bone structure of bovine-derived bone particles and leverages the bioactivity of hyaluronic acid to significantly enhance the material'sBiocompatibilityHe GuRegenerative Efficacy，Induction of Osteogenic Factor Expression, imparting the material with higherHydrophilicity, significantly promoting early osteogenesis and further facilitatingSuccess Rate of Implant Surgery; Hyaluronic acid also hasPromote Wound Healing, to a certain extentAnti-inflammatoryand other effects.

Aosu Bone Filling Material，AdoptPatented Low-Temperature Processing Technology, making the material's micro-porous structure more closely resemble that of alveolar bone to ensure osteoconductivity; low-temperature calcination also endows the material with more suitableCrystallinity, its degradation rate better matches the rate of new bone formation, resulting in greater new bone volume over the same period; Aosu bone graft substitute also featuresLarger Specific Surface Area, enhance hydrophilicity and blood adsorption capacity, and promote osteogenesis through multiple mechanisms.

Leveraging the properties of barrier membranes to block fibroblasts from surrounding soft tissues, allowing osteoblasts at the bone surface sufficient time to proliferate, ultimately achievingTissue Regeneration, Targeted Repairpurpose.

Bovine pericardium is the most widely used extracellular matrix material, offering mechanical advantages and dense fibrous tissue compared to other tissue materials. Its application in GBR canEffective Barrier to Soft Tissue, protect the bone growth space.

Excellent mechanical properties, easy to handle

Long-Lasting Barrier, Ensuring Lifelong Protection for Bone Growth

Dual-Layer Dense-Sparse Structure Membrane: Providing Dual Protection for Bone Regeneration

Scan the QR code on the poster to add our assistant and reserve a spot for the live broadcast.

Zhao Zheng

Director, Vice President, and Secretary to the Board of Directors of BioRegen

Director, Vice President, and Secretary of the Board of Directors of Shaanxi BioRegen Regenerative Medicine Co., Ltd.

Bachelor of Science in Biological Sciences, Fudan University

MBA, Washington University in St. Louis

6 Years of Experience in Investment, Financing, and Management in the Healthcare Industry

10 Years of Experience at Big Four Accounting Firms, Leading Consulting Firms, and Investment Banks

Zhang Yongjie

Chief Technology Officer, BioRegen

Ph.D. in Stomatology, Fourth Military Medical University

Vice Chair, Branch of Tissue Engineering and Regenerative Medicine, China

Vice Chairman, China Collaborative Innovation Center for Tissue Engineering and Regenerative Medicine

Scientist of the National “863” and “973” Programs

First Prize of the National Science and Technology Progress Award

Developed multiple domestic tissue engineering and regenerative medicine products:

In 2007, China’s first tissue-engineered product—tissue-engineered skin—was developed, and this achievement was selected as a representative milestone of the ten-year leap forward in China’s medical science and technology.

Developed the world’s first tissue-engineered corneal product in 2015, selected as one of the “Top 10 Advances in China’s Biopharmaceutical Technology in 2015”

Wang Peng

General Manager, Regenerative Medical Dentistry Division, Bai'ao Regeneration

Renmin University of China Zhongrui Business School Pharmaceutical EMBA

Tianjin Medical University, Clinical Medicine Program

20 years of experience in sales and management of medical devices at foreign-invested enterprises and domestic listed companies, leading a Chinese medical device brand to achieve the largest market share in the industry.

Baiao Regenerative Medicine is a technology-driven biotech materials company powered by regenerative medicine technologies. The company and its subsidiaries are primarily engaged in the business of Class III implantable medical devices, organoid-based skin applications, functional skincare products, and innovative CDMO services for skincare.

The company’s core team was among the first in China to conduct regenerative medicine research, achieving three world-class scientific breakthroughs. It received the First Prize of the National Science and Technology Progress Award—the first such honor in the field of regenerative medicine—and its achievements were twice recognized as one of the Top Ten Advances in Chinese Pharmaceutical Biotechnology. As a pioneer in innovative R&D for regenerative medicine in China, the company has established itself as a leader in this sector.

We have pioneered the industrialization of regenerative medicine in China, with a portfolio comprising four national-level high-tech enterprises and four enterprises above designated size. Bai’ao Regenerative Medicine is recognized as a National Intellectual Property Advantage Enterprise, serves as the President Unit of the Shaanxi Medical Device Association, and is listed as a Shaanxi Pre-IPO Reserve Enterprise, a Shaanxi “Specialized, Refined, Differential, and Innovative” (SRDI) Enterprise, a Shaanxi Intelligent Manufacturing Demonstration Enterprise, and a Shaanxi Intellectual Property Advantage Enterprise. It also hosts the Xi’an Engineering Technology Center for Regenerative Medicine. The company currently possesses over 130,000 square meters of industrialization space (including facilities under construction), of which more than 70,000 square meters are GMP-certified production areas. With total investments exceeding RMB 100 million in R&D and industrialization equipment, it has emerged as a leader in the industrialization of regenerative medicine in China.

“Artery Select New Product Showcase” is a live-streaming program under the “Artery Select” brand, dedicated to supporting healthcare companies in launching innovative products. The program’s mission is to empower the milestone launch of every medical innovation product.

Scan the QR code below to contact the assistant and schedule a live stream (if already added, please proactively reach out to the assistant).

Scan the QR code below to download the VCBeat app and register to watch the live stream.

Contact the assistant and send a screenshot of the live stream to enter the lucky draw for a chance to win a [15-day trial membership of VBInsight Industry Think Tank].